Jylamvo FDA Approval History
FDA Approved: Yes (First approved November 29, 2022)
Brand name: Jylamvo
Generic name: methotrexate
Dosage form: Oral Solution
Company: Shorla Oncology Inc.
Treatment for: Acute Lymphoblastic Leukemia, Mycosis Fungoides, Non-Hodgkin's Lymphoma, Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Psoriasis
Jylamvo (methotrexate) is a folate analog metabolic inhibitor used for the treatment of acute lymphoblastic leukemia, mycosis fungoides, non-Hodgkin lymphoma, rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and psoriasis.
- Jylamvo is indicated for the:
- treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen
- treatment of adults with mycosis fungoides
- treatment of adults with relapsed or refractory non-Hodgkin lymphoma as part of a metronomic combination regimen
- treatment of adults with rheumatoid arthritis
- treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA)
- treatment of adults with severe psoriasis.
Development timeline for Jylamvo
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.